Join
Live feed
·
PRReleasevia Quantisnow
Relay Therapeutics Inc. logo

Relay Therapeutics Discloses Anticipated Registrational Path for RLY-4008 in Cholangiocarcinoma and Growing Breast Cancer Franchise at Virtual Analyst and Investor Event

ByQuantisnow·Wall Street's wire, on your screen.
RLAY· Relay Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RLAY (Relay Therapeutics Inc.) and more on Quantisnow.